Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
← catalyst calendarSponsored by BioArctic AB (industry) · BIOA-B.ST — their whole pipeline →. With Worldwide Clinical Trials.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
38actual
Sites
7
Countries
Poland, Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-24 | actual | When the study began enrolling |
| Primary completion | 2026-08-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-17 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Parkinson Disease
- Multiple System Atrophy
Interventions
- Drug: exidavnemab
- Drug: Placebo Comparator
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious adverse events (SAEs).
measured From first dose to Day 176
Permalink · BIOA-B.ST's whole pipeline · Catalyst calendar · Every registered study · What changed